This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NASDAQ Welcomes KYTHERA Biopharmaceuticals To The NASDAQ Stock Market

NEW YORK, Oct. 16, 2012 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today that trading of KYTHERA Biopharmaceuticals (Nasdaq:KYTH), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, commenced on The NASDAQ Stock Market on October 11, 2012.

KYTHERA Biopharmaceuticals strives to develop prescription products using an approach that relies on biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. KYTHERA's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. Their product, ATX-101, is currently in Phase III clinical development for the reduction of submental fat, which is commonly presented as unwanted fat under the chin. 

"KYTHERA Biopharmaceuticals strives to break ground in the growing aesthetics market, with an initial focus on developing a facial injectable drug for the treatment of submental fat, or double chin," said Bob McCooey, Senior Vice President, NASDAQ OMX Corporate Client Group. "We are proud to welcome KYTHERA to the NASDAQ family and look forward to supporting their endeavors as a public company."

"We founded KYTHERA Biopharmaceuticals seven years ago with a vision to create a new kind of biotechnology company using great science, clinical rigor and real innovation to address unmet needs in the rapidly-growing aesthetic medicine market," said Keith Leonard, KYTHERA's President and CEO. "The success of our IPO reflects the hard work, creativity and diligence of our employees, advisors and the physician community. We are delighted to join the ranks of other NASDAQ OMX public companies as we look to build KYTHERA into a leading aesthetics company."

Since its inception, NASDAQ OMX has consistently been the exchange of choice for progressive and cutting-edge health care and biopharmaceutical companies like KYTHERA Biopharmaceuticals. In 2012, NASDAQ has welcomed over 78 percent of the health care companies that have listed on U.S. markets. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,063.93 -16.21 -0.09%
S&P 500 2,113.05 -4.64 -0.22%
NASDAQ 5,069.2950 -22.79 -0.45%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs